journal
MENU ▼
Read by QxMD icon Read
search

Oncology Research and Treatment | Page 4

journal
https://read.qxmd.com/read/30959511/stadien-des-prostatakarzinoms-und-unmet-medical-need
#61
Jörg Klier
Männer mit Prostatakarzinom haben eine gute Prognose, wenn die Erkrankung in einem frühen Stadium erkannt und behandelt wird. In späteren Stadien steigt das Progressions- und Mortalitätsrisiko hingegen deutlich. Das gilt auch für das nicht-metastasierte kastrationsresistente Prostatakarzinom (M0CRPC, nm-CRPC), bei dem das Progressionsrisiko insbesondere bei kurzer PSA-Verdopplungszeit deutlich erhöht ist. Für entsprechende Patienten gab es lange - außer der klassischen Androgendeprivation - keine Therapieoptionen...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30959510/vorwort
#62
Thorsten Schlomm, Thomas Steuber, Henrik Suttmann
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30959509/spartan-gezielte-analyse-der-resistenzen
#63
Martin Bögemann
Beim metastasierten kastrationsresistenten Prostatakarzinom (mCRPC) erfolgt heute eine Sequenztherapie. Daher müssen sich neue Wirkstoffe, die früher - im nicht-metastasierten kastrationsresistenten Stadium (M0CRPC) mit hohem Metastasierungsrisiko - eingesetzt werden, ebenfalls in diese Sequenz einfügen.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30959508/apalutamid-eine-neue-option-f%C3%A3-r-die-therapie-des-hochrisiko-m0crpc
#64
Christian Schwentner
Das Auftreten von Metastasen stellt beim nicht-metastasierten kastrationsresistenten Prostatakarzinom (M0CRPC) einen Wendepunkt in der Erkrankung dar. Apalutamid, ein neuer Androgenrezeptorinhibitor (ARI), verlängerte in der SPARTAN-Studie beim Hochrisiko-M0CRPC im Vergleich zu Placebo das metastasenfreie Überleben (MFS) signifikant. Ähnliches ergab die PROSPER-Studie für Enzalutamid. Internationale Leitlinien empfehlen die beiden Wirkstoffe seit 2018 für die Therapie des Hochrisiko-M0CRPC.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30959507/editorial-board-contents-imprint
#65
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30955009/efficacy-and-safety-of-alk-tyrosine-kinase-inhibitors-in-elderly-patients-with-advanced-alk-positive-non-small-cell-lung-cancer-findings-from-the-real-life-cohort
#66
Aseel Bedas, Nir Peled, Natalie Maimon Rabinovich, Moshe Mishaeli, Tzippy Shochat, Alona Zer, Ofer Rotem, Aaron M Allen, Jair Bar, Elizabeth Dudnik
BACKGROUND: Little is known regarding the anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) efficacy and safety in the elderly. OBJECTIVES AND METHODS: Consecutive patients (n = 53) with ALK-positive advanced non-small cell lung cancer treated with an ALK TKI were identified through internal databases of three cancer centers and divided into groups A (< 65 years old; n = 34) and B (≥65 years old; n = 19). Progression-free survival (PFS), ALK TKI safety and overall survival (OS) were assessed...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30943501/a-dose-escalating-pilot-study-nct03017404-of-pegylated-liposomal-doxorubicin-and-cyclophosphamide-followed-by-docetaxel-administration-as-a-neoadjuvant-chemotherapy-regimen-in-patients-with-locally-advanced-breast-cancer
#67
Meng Cheng, Zhenchuan Song, Yixin Qi, Xinle Wang, Lina Zhang, Jiajie Shi, Mingxia Wang
BACKGROUND: Pegylated liposomal doxorubicin (PEG-LD) has a comparable efficacy but a distinct toxicological profile compared with free doxorubicin. The use of PEG-LD and cyclophosphamide followed by docetaxel regimen as neoadjuvant chemotherapy has not been well established. OBJECTIVES: We aimed to assess the maximum tolerated dose (MTD) and toxicity of this regimen in patients with locally advanced breast cancer. METHODS: A total of 19 patients were enrolled in this trial...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30870846/prognostic-significance-of-metastatic-lymph-node-ratio-in-patients-with-pn3-gastric-cancer-who-underwent-curative-gastrectomy
#68
Ahmet Bilici, Fatih Selcukbiricik, Mesut Seker, Basak B Oven, Omer Fatih Olmez, Ozcan Yildiz, Oktay Olmuscelik, Jamshid Hamdard, Ozgur Acikgoz, Asli Cakir, Yersu Kapran, Emre Balik, Mustafa Oncel
BACKGROUND: Lymph node involvement is an important prognostic factor in patients with gastric cancer. The aim of this study was to determine the prognostic significance of metastatic lymph node ratio (MLNR) and compare it to the number of lymph node metastasis in pN3 gastric cancer. METHODS: We retrospectively analyzed 207 patients with pN3 gastric cancer who had undergone radical gastrectomy. Prognostic factors and MLNR were evaluated by univariate and multivariate analysis...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30865995/society-bulletins
#69
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30865994/meetings-and-conferences
#70
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30865993/editorial-board-contents-journal-information
#71
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30844820/-agsmo-jahreskongress-2019-supportive-therapie-bei-krebs-berlin-15-16-m%C3%A3-rz-2019
#72
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30836373/combination-of-immunotherapy-and-brain-radiotherapy-in-metastatic-melanoma-a-retrospective-analysis
#73
Giulia Galli, Stefano Cavalieri, Lorenza Di Guardo, Carolina Cimminiello, Federico Nichetti, Francesca Corti, Monica Alicia Garcia, Brigida Pappalardi, Carlo Fallai, Filippo de Braud, Marco Platania, Michele Del Vecchio
BACKGROUND: Up to 40% of patients with metastatic melanoma (MM) develop brain metastases. Radiotherapy (RT) may potentiate the effects of immunotherapy (IO), even on distant sites (abscopal effect). MATERIAL AND METHODS: We retrospectively analyzed all our MM patients treated with IO within 6 months before/after brain RT between 2012 and 2016. Progression-free (PFS) and overall survival (OS) were estimated with the Kaplan-Meier method and compared with those of controls treated with IO during the same period...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30820020/germ-cell-tumors-with-malignant-somatic-transformation-a-mayo-clinic-experience
#74
Caleb J Scheckel, Heidi E Kosiorek, Richard Butterfield, Thai H Ho, Talal Hilal
BACKGROUND: Germ cell tumors (GCTs) with malignant somatic transformation (MST) represent an uncommon variant of what is typically a curable malignancy. There is a paucity of data on time of somatic transformation, response to conventional therapy, and survival outcomes of different somatic subtypes. METHODS: After obtaining institutional review board (IRB) approval, we searched our institutional database from 1982 to 2017 and identified patients with GCTs with MST...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30814474/multidisciplinary-tumor-board-recommendations-for-oligometastatic-malignancies-a-prospective-single-center-analysis
#75
Christian Galata, Elisabeth Wimmer, Bernd Kasper, Frederik Wenz, Christoph Reißfelder, Jens Jakob
BACKGROUND: The treatment of oligometastatic disease is challenging and few data exist to guide treatment decisions. The objective of this study was to improve the data on the prevalence and treatment of patients with oligometastatic disease. METHODS: We conducted a prospective single-center analysis that included all consecutive patients discussed in multidisciplinary tumor boards (MDT) between February and July 2017. Patients with oligometastatic disease were identified and treatment strategies were evaluated...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30799429/patterns-of-lymph-node-metastasis-in-differentiated-thyroid-cancer-clinical-implications-with-particular-emphasis-on-the-emerging-role-of-compartment-oriented-lymph-node-dissection
#76
George H Sakorafas, Andreas Koureas, Iliana Mpampali, Dimitrios Balalis, Dimitrios Nasikas, Sotirios Ganztzoulas
Recent advances in modern imaging allow an accurate identification of involved or suspicious lymph nodes within the nodal compartments of the neck. Careful ultrasonographic lymphatic mapping of the neck by an experienced radiologist allows a targeted, compartment-oriented (or selective) lymph node dissection to be performed instead of the more extensive modified radical lymph node dissection. Compartment-oriented lymph node dissection necessitates the close cooperation of an experienced radiologist with a particular interest in thyroid and neck ultrasonography...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30799422/a-rare-case-of-mixed-adenoneuroendocrine-carcinoma-manec-of-the-gastroesophageal-junction-with-her2-neu-overexpression-and-distinct-orbital-and-optic-nerve-toxicity-after-intravenous-administration-of-cisplatin
#77
Thomas Golombek, Robert Henker, Matus Rehak, Ulf Quäschling, Florian Lordick, Maren Knödler
BACKGROUND: Mixed adenoneuroendocrine carcinomas (MANECs) are rare malignancies with both neuroendocrine and non-neuroendocrine components. To date, the prognosis of gastroenteropancreatic MANECs remains dismal, and treatment options are mainly based on guidelines for the treatment of pure neuroendocrine carcinomas or small cell lung cancer. Established first-line therapy in the metastatic situation is cisplatin and etoposide. Platinum derivatives are known to cause a variety of side effects also involving the visual system...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30799404/non-clear-cell-renal-cell-carcinoma-pathology-and-treatment-options
#78
REVIEW
Marit Ahrens, Sebastian Scheich, Arndt Hartmann, Lothar Bergmann
Non-clear cell renal cell carcinomas (nccRCC) are rare diseases with heterogeneous histopathologically and genetically defined entities. The clinical data on optimal systemic treatments of nccRCC is rather limited. In this review, the current World Health Organization (WHO) classification of nccRCC based on histopathologic and genetic findings is reported. Regarding systemic treatment options, the most commonly used agents are mTOR inhibitors like everolimus or temsirolimus, or tyrosine kinase inhibitors like sunitinib...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30799393/a-single-center-retrospective-study-of-patients-with-double-primary-cancers-breast-cancer-and-egfr-mutant-non-small-cell-lung-cancer
#79
Teresa Moran, Vanesa Quiroga, Beatriz Cirauqui, Laia Vila, Maria Gil-Moreno, Enric Carcereny, Mireia Margeli, Ana Muñoz-Marmol, Jose Luis Mate, Jose Maria Velarde, Miguel Angel Molina, Rafael Rosell
BACKGROUND: Second primary malignancies (SPM) in the lung are not common in breast cancer (BC) patients. EGFR-mutant lung cancer (LC) is a separate molecular subset, and the co-existence of EGFR-mutant LC and BC has not been explored. We hypothesized that EGFR-mutant LC patients could have higher rates of primary BC than those with EGFR-wild type (WT). METHODS: We collected data on clinical and molecular characteristics and outcomes of female patients with LC and a previous or simultaneous history of primary BC treated in our hospital from 2008 to 2014...
2019: Oncology Research and Treatment
https://read.qxmd.com/read/30721915/erratum
#80
(no author information available yet)
No abstract text is available yet for this article.
2019: Oncology Research and Treatment
journal
journal
48348
4
5
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"